Results 101 to 110 of about 279,790 (190)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Experimental Hematology & Oncology
Relapsed/refractory T cell-derived malignancies present with high heterogeneity and poor prognoses. Recently, chimeric antigen receptor (CAR)-T cell therapy has shown remarkable safety and efficacy in the treatment of B cell-derived malignancies. However,
Haiqiong Zheng, Houli Zhao, Shi Han, Delin Kong, Qiqi Zhang, Mingming Zhang, Yijin Chen, Meng Zhang, Yongxian Hu, He Huang   +9 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Antibiotic Use Before CAR-T Treatment Is Associated with Inferior Outcomes in DLBCL Lymphoma Patients

Biomedicines
Background/Objectives: CAR-T-cell therapy has become a key treatment for relapsed or refractory hematologic malignancies such as diffuse large B-cell lymphoma (r/r DLBCL), although patient outcomes differ considerably.
Anja Bullegas, Inna Shaforostova, Katja Seipel, Marie-Noëlle Kronig, Henning Nilius, Ulrike Bacher, Thomas Pabst   +6 more
doaj   +1 more source

Boosting CAR-T cell therapy with CRISPR technology

hLife
Chimeric antigen receptor (CAR)-T cell therapy has made remarkable breakthroughs in treating cancers, especially hematologic malignancies, yet its broader application in cancer treatment is hindered by multiple challenges.
Liyanran Yan, Shanzi Gao, Xinhui Wang, Xintao Zhou, Praopim Limsakul, Yiqian Wu   +5 more
doaj   +1 more source

CAR-T cell-derived exosomes: a new perspective for cancer therapy

Stem Cell Research & Therapy
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects.
Farnaz Sani, Shabnam Shojaei, Seyed Amirhossein Tabatabaei, Mohammadhossein Khorraminejad-Shirazi, Mona Latifi, Mahsa Sani, Negar Azarpira   +6 more
doaj   +1 more source

Hypogammaglobulinemia due to CAR T‐cell therapy [PDF]

Pediatric Blood & Cancer, 2017
Andrew Doan, Michael A. Pulsipher
openaire   +2 more sources

Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells

MedComm
The challenge of disease relapsed/refractory (R/R) remains a therapeutic hurdle in chimeric antigen receptor (CAR) T‐cell therapy, especially for hematological diseases, with chronic lymphocytic leukemia (CLL) being particularly resistant to CD19 CAR T ...
Yaqing Qie, Martha E. Gadd, Qing Shao, Tommy To, Andrew Liu, Shuhua Li, Rocio Rivera‐Valentin, Farah Yassine, Hemant S. Murthy, Roxana Dronca, Mohamed A. Kharfan‐Dabaja, Hong Qin, Yan Luo   +12 more
doaj   +1 more source

Mathematical Modeling of the CAR T-cell Therapy [PDF]

, 2020
Elliott, Samantha, Kose, Emek, Zollinger, Elizabeth   +2 more
core   +1 more source

The TCR in CAR T cell therapy: use it or lose it? [PDF]

Cancer Gene Ther
Liseth O, Vile R.
europepmc   +1 more source

CAR T-cell therapy induced pseudoprogression. [PDF]

Front Immunol
Dean EA.
europepmc   +1 more source